Successful donor leukocyte transfusion at molecular relapse for a patient with acute myeloid leukemia who was treated with allogenic bone marrow transplantation: importance of the monitoring of minimal residual disease by WT1 assay.
We report here that a patient with relapsed AML after allogeneic bone marrow transplantation achieved and maintained complete remission (CR) after effective donor leukocyte transfusion (DLT), without the occurrence of GVHD and marrow aplasia, for more than 21 months. This continuous CR maintenance is mainly due to the application of DLT at molecular relapse that was diagnosed by monitoring minimal residual disease (MRD) by the quantitation of WT1 (Wilms tumor gene) expression levels (WT1 assay). The present case demonstrates that early application of DLT at molecular relapse is essential for the improvement of the efficacy of DLT for relapsed AML after BMT.
Ogawa
H
H
Department of Medicine III, Osaka University Medical School, Suita City, Japan.
Tsuboi
A
A
Oji
Y
Y
Tamaki
H
H
Soma
T
T
Inoue
K
K
Sugiyama
H
H
D000208:Acute Disease; D014408:Biomarkers, Tumor; D016026:Bone Marrow Transplantation; D004268:DNA-Binding Proteins / Q000032:analysis*; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D017708:Leukocyte Transfusion; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000175:diagnosis; D012074:Remission Induction; D014157:Transcription Factors / Q000032:analysis*; D025721:WT1 Proteins; D016335:Zinc Fingers
D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D014157:Transcription Factors; D025721:WT1 Proteins